ADA 2026 Diabetes Guidelines: What’s New and What It Means

The American Diabetes Association (ADA) has released its updated Standards of Care in Diabetes—2026, and it’s a significant shift. Instead of focusing mainly on blood glucose numbers, the new guidelines push for earlier, broader protection of the heart, kidneys and liver — sometimes from the moment of diagnosis.

While this is a US guideline, it carries real weight here too. Australian specialists, GPs and organisations like Diabetes Australia often watch these updates closely, as they shape global thinking on best-practice diabetes care.

The short version

• Continuous glucose monitors (CGMs) are now recommended from diagnosis for anyone using insulin, not just after problems arise.
• Automated insulin delivery (sometimes called “closed-loop” systems) is now the preferred way to deliver insulin for most people with type 1 diabetes.
• For type 2 diabetes, SGLT2 inhibitors and GLP-1-based medicines are recommended earlier — for heart, kidney, liver and weight benefits — not only after metformin stops working.
• In Australia, these changes may influence future local guidelines, but PBS (Pharmaceutical Benefits Scheme) access rules haven’t automatically changed.

What’s actually new

The ADA’s Standards of Care are updated every year, drawing on the latest research. The 2026 edition, alongside a related joint consensus report from the ADA and the European Association for the Study of Diabetes (EASD), moves away from a “glucose-first” model.

Instead, it treats diabetes as a condition that affects the whole body — heart, kidneys, liver and more — and recommends treating these risks early and together, rather than waiting for complications to appear.

Key updates include:

• CGM use from day one for people starting insulin, rather than waiting until there are signs of trouble like frequent low blood glucose (hypoglycaemia).
• No pre-testing required before starting automated insulin delivery in type 1 diabetes — previously, some guidance suggested checking antibody or C-peptide levels (a measure of how much insulin your own body still makes) first.
• Earlier use of SGLT2 inhibitors and GLP-1 therapies in type 2 diabetes, based on a person’s heart, kidney, liver or weight-related risks — even before trying metformin, in some cases.
• Combination therapy — using an SGLT2 inhibitor together with a GLP-1-based medicine — is now considered reasonable earlier on for people with heart failure, chronic kidney disease or cardiovascular disease.
• A lower blood pressure target (below 120 systolic) may be appropriate for people at high cardiovascular or kidney risk, if it can be reached safely.
• Greater attention to MASLD/MASH (metabolic dysfunction-associated steatotic liver disease, previously called fatty liver disease), sleep health, mental health and gum disease as part of overall diabetes care.
• A reminder to include oral glucose in hypoglycaemia first-aid kits, and updated advice on combination treatments for painful nerve damage (neuropathy).

What the evidence shows

These changes aren’t based on guesswork. According to the research summarised in the update, large trials over recent years have consistently shown that SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of heart attacks, heart failure hospitalisations and kidney decline — benefits that appear even in people without high blood glucose readings.

Similarly, automated insulin delivery systems (which automatically adjust insulin based on CGM readings) have shown improved time spent in a healthy glucose range, with less effort and fewer severe lows for many users.

It’s worth noting this is still an evolving area. Guidelines reflect the best current evidence, but individual results vary, and not every recommendation will suit every person.

Who this affects

• Type 1 diabetes: The push toward automated insulin delivery as a preferred option is the headline change. If you’re currently on multiple daily injections, this might be worth discussing with your endocrinologist or diabetes educator.
• Type 2 diabetes: The emphasis on earlier SGLT2 inhibitor and GLP-1 use — especially for people with heart, kidney or liver risk factors — is the biggest shift, moving away from a step-by-step approach starting with metformin alone.
• Prediabetes and gestational diabetes: These guidelines are less directly focused on these groups, though the broader emphasis on cardiometabolic health (heart, metabolism and blood vessel health together) is relevant background.

What this means in Australia

It’s important to understand that an ADA recommendation is not the same as an Australian standard of care, and it doesn’t change what’s funded through the PBS.

In Australia, prescribing is guided by the Therapeutic Goods Administration (TGA) approvals, PBS listing criteria, and local clinical guidelines from bodies like the Royal Australian College of General Practitioners (RACGP) and Diabetes Australia. These Australian bodies often take time to review international evidence before updating local advice, and PBS subsidy rules depend on specific approved indications — meaning a medicine might be recommended by the ADA for a purpose it isn’t funded for here.

• SGLT2 inhibitors already have reasonably broad PBS access for type 2 diabetes, heart failure and kidney-related indications in Australia, so this area may align fairly well.
• GLP-1 medicines have more restricted PBS access, particularly when used mainly for weight management rather than a listed diabetes indication. Supply issues have also affected availability at times.

What we still don’t know

Guidelines like this reflect population-level evidence — what tends to work best, on average, for groups of people with certain risk profiles. They don’t replace individual assessment.

We also don’t yet have long-term, real-world data on how automated insulin delivery performs for all types of users over many years, or how earlier medicine use in very newly diagnosed people affects outcomes decades down the track.

What this means for you

• If you have type 1 diabetes, consider asking your diabetes team whether automated insulin delivery might be suitable for you, and whether it’s accessible through the NDSS (National Diabetes Services Scheme) or private funding.
• If you have type 2 diabetes, ask your GP or endocrinologist whether your current heart, kidney or liver risk factors might make an SGLT2 inhibitor or GLP-1 medicine worth discussing — remembering that any medicine change should always be made with your healthcare team, never on your own.
• Don’t assume a medicine mentioned in the news is automatically PBS-subsidised for your situation — ask directly.
• Keep up routine screening: annual eye checks, kidney function tests and foot checks remain essential, regardless of these updates.

Guideline updates like this are a reminder that diabetes care keeps evolving, with a growing focus on protecting the whole body, not just blood glucose. For more on managing your diabetes day to day, explore our recipes, daily menus and practical guides elsewhere on Diabetes Clarity.